3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

[1]  C. Bombardier.  An evidence-based evaluation of the gastrointestinal safety of coxibs. , 2002, The American journal of cardiology.

[2]  M. Noh,et al.  2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[3]  J. Pérez,et al.  Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[4]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[5]  R. S. Rogers,et al.  4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.

[6]  V. Segarra,et al.  Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.

[7]  D. Riendeau,et al.  A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[8]  M. Percival,et al.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[9]  R Gordon,et al.  2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[10]  S. Luell,et al.  Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  D. Riendeau,et al.  Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. , 1997, Canadian journal of physiology and pharmacology.

[12]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[13]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[14]  Jilly F. Evans,et al.  Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. , 1996, Biochemical pharmacology.

[15]  C. Brideau,et al.  A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors , 1996, Inflammation Research.

[16]  D. Riendeau,et al.  Synthesis and biological evaluation of 2,3-diarylthiophenes as selective cox-2 inhibitors. part II: Replacing the heterocycle , 1996 .

[17]  S. Boyce,et al.  Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. , 1995, The Journal of pharmacology and experimental therapeutics.